Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 6, 2010

View Archived Issues

GSK to develop Anacor's new antibiotic for Gram-negative infections

Bristol-Myers Squibb claims new JAK2 inhibitors

Santhera discloses new MC4 receptor antagonists

New FPS inhibitors discovered at Novartis

Dr. Reddy's Laboratories and Pulmagen Therapeutics claim new PPAR-gamma agonists

CANOE trial data support use of Avandamet to prevent type 2 diabetes

Scientists report regional changes in brain gray matter density in patients with IBS

PF-3845 has antiallodynic effects in preclinical study

Scientists explore neuroprotective role of URB-597 in models of retinal neurodegeneration

Preclinical study implicates GPR55 in regulation of osteoclast number and function

Telormedix and Swiss TPH join to study TMX-201 in malaria and Buruli ulcer

TapImmune and Mayo Clinic partner to develop smallpox vaccine technology

FDA issues complete response letter for Luveniq NDA in noninfectious uveitis

Gemin X secures funding for obatoclax development

Resolor approved in Switzerland for idiopathic chronic constipation

FDA accepts NDA for gadobutrol injection in MRI of CNS

BrainCells acquires Proximagen's sabcomeline for major depressive disorder

Affymax and Takeda outline U.S. registration strategy for Hematide

FDA approves new docetaxel injection concentrate formulation for cancer

YM concludes dose escalation in phase I CYT-387 trial in myelofibrosis

EMA's CHMP issues positive opinion on Relistor in prefilled syringes

Vicept presents clinical data on V-101 in rosacea-associated erythema

NIH provides grant for phase I/II AEZS-108 trial in advanced prostate cancer

Tekmira files IND application with FDA for PLK1-SNALP in solid tumors

Takeda presents new glucokinase activators

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 6, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
Cytospire raises £61M series A to target EGFR in solid tumors
BioWorld
Next-generation T-cell engager (TCE) specialist Cytospire Therapeutics Ltd. has raised £61 million (US$82.7 million) in a series A round, equipping it to advance...
Bio Korea 2026: US policy risks shift to execution framework
BioWorld
Regulatory uncertainty that dominated the life science sector in 2025 is transitioning into an execution framework for biotechnology companies, provided companies...
Regulatory actions for May 5, 2026
BioWorld
Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Adma, Applied...